Neuropathic Pain
Conditions
Brief summary
Important pharmacological agents for treatment of chronic neuropathic pain such as ketamine block NMDA receptors. Nitrous oxide, an inhalant agent used extensively In anesthesia, also have antagonist property of NMDA receptors. The investigators hypothesize that prolonged treatment with N2O can alleviate chronic neuropathic pain of different causes (e.g. diabetic neuropathy, post herpetic neuralgia etc.).
Detailed description
Important pharmacological agents for treatment of chronic neuropathic pain such as ketamine block NMDA receptors. Nitrous oxide, an inhalant agent used extensively In anesthesia, also have antagonist property of NMDA receptors. The investigators hypothesize that prolonged treatment with N2O can alleviate chronic neuropathic pain of different causes (e.g. diabetic neuropathy, post herpetic neuralgia etc.). In order to examine our theory we Will recruit 40 patients aged 18-65 that suffer from chronic neuropathic pain. The patients will be divided to two groups of which half will receive treatment with N2O and half with placebo (pure O2) as a repeated weekly treatment for 4 weeks. At the beginning of the each session the patient will be asked to fill questionnaires regarding their pain quality and severity
Interventions
DRUGN2O
DRUGOxygen
Sponsors
Tel-Aviv Sourasky Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* men and women at the age 18-65 * patient that suffer from chronic neuropathic pain * VAS\>40 * DN4 score \>4 * takes pain medication on a regular basis * Didn't get epidural injection for the pas month * signed an informed consent form
Exclusion criteria
* patients that suffer from chronic lung disease. * patients with cancer * patients with heart disease * pregnant and lactate woman * patients that suffer from depression
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| change in adult pain as measured by visual Analog Scale for Pain (VAS Pain) | baseline and average of week for 4 weeks | Assessment of pain in the last 24 hours before the visit by VAS |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| change in adult pain as measured by Short-Form McGill Pain Questionnaire (SF-MPQ) | baseline and average of week for 4 weeks | Assessment of pain in the last 24 hours before the visit by SF-MPQ |
Countries
Israel
Outcome results
None listed